Login to Your Account



New Phase III Data Strong

Biogen Hemo Therapy Travels 'A-LONG' Pathway to Success

By Randy Osborne
Staff Writer

Tuesday, July 9, 2013
Last fall, when Biogen Idec Inc. and partner Swedish Orphan Biovitrum (Sobi) made public the Phase III from A-LONG, a trial testing their long-lasting recombinant factor VIII candidate – since branded Eloctate – in hemophilia A, most analysts were pleased but cautious about the treatment's chances anytime soon to dominate Advate, marketed by Baxter Healthcare Corp.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription